Exelixis Inc (EXEL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Exelixis Inc stock (EXEL) is currently trading at $42.78. Exelixis Inc PE ratio is 14.95. Exelixis Inc PS ratio (Price-to-Sales) is 4.80. Analyst consensus price target for EXEL is $46.83. WallStSmart rates EXEL as Moderate Buy.
- EXEL PE ratio analysis and historical PE chart
- EXEL PS ratio (Price-to-Sales) history and trend
- EXEL intrinsic value — DCF, Graham Number, EPV models
- EXEL stock price prediction 2025 2026 2027 2028 2029 2030
- EXEL fair value vs current price
- EXEL insider transactions and insider buying
- Is EXEL undervalued or overvalued?
- Exelixis Inc financial analysis — revenue, earnings, cash flow
- EXEL Piotroski F-Score and Altman Z-Score
- EXEL analyst price target and Smart Rating
Exelixis Inc
📊 No data available
Try selecting a different time range
EXEL Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Exelixis Inc (EXEL)
EXEL trades at a significant discount to its Graham intrinsic value of $130.10, offering a 67% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Exelixis Inc (EXEL) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, return on equity, operating margin. Overall metrics suggest strong investment potential with favorable risk/reward.
Exelixis Inc (EXEL) Key Strengths (6)
Every $100 of shareholder equity generates $36 in profit
Keeps $39 of every $100 in revenue after operating costs
Earnings per share surging 84.20% year-over-year
Keeps $34 of every $100 in revenue as net profit
103.05% of shares held by major funds and institutions
Large-cap company with substantial market presence
Supporting Valuation Data
Exelixis Inc (EXEL) Areas to Watch (4)
Paying a premium for growth, expensive relative to earnings expansion
Premium valuation at 4.8x annual revenue
Premium pricing at 5.0x book value
Modest revenue growth at 5.60%
Exelixis Inc (EXEL) Detailed Analysis Report
Overall Assessment
This company scores 72/100 in our Smart Analysis, earning a B grade. Out of 10 metrics analyzed, 6 register as strengths (avg 9.8/10) while 4 fall into concern territory (avg 4.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Operating Margin, EPS Growth. Profitability is solid with Return on Equity at 35.50%, Operating Margin at 39.40%, Profit Margin at 33.70%. Growth metrics are encouraging with EPS Growth at 84.20%.
The Bear Case
The primary concerns are PEG Ratio, Price/Sales, Price/Book. Some valuation metrics including PEG Ratio (2.27), Price/Sales (4.80), Price/Book (4.96) suggest expensive pricing. Growth concerns include Revenue Growth at 5.60%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 35.50% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 5.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of Return on Equity and Operating Margin makes a compelling case at current levels. The key risk is PEG Ratio, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
EXEL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
EXEL's Price-to-Sales ratio of 4.80x trades at a deep discount to its historical average of 23.11x (7th percentile). The current valuation is 96% below its historical high of 118.77x set in Nov 2016, and 21% above its historical low of 3.97x in Aug 2012.
WallStSmart Analysis Synopsis
Data-driven financial summary for Exelixis Inc (EXEL) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Exelixis Inc is a mature, profitable business with steady cash generation. Revenue reached 2.3B with 6% growth year-over-year. Profit margins are strong at 33.7%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 3550.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 33.7% and operating margin of 39.4% demonstrate strong pricing power and operational efficiency.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Exelixis Inc.
Bottom Line
Exelixis Inc is a well-established business delivering consistent profitability with 33.7% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Exelixis Inc(EXEL)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.